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Abstract: Type 2 diabetes is widespread and its prevalence is increasing rapidly. In the US 
alone, approximately 41 million individuals have prediabetes, placing them at high risk for 
the development of diabetes. The pathogenesis of type 2 diabetes involves inadequate insulin 
secretion and resistance to the action of insulin. Suggestive data link insulin resistance and 
accompanying hyperglycemia to an excess of abdominal adipose tissue, a link that appears to 
be mediated partially by adipocyte secretion of multiple adipokines that mediate inﬂ  ammation, 
thrombosis, atherogenesis, hypertension, and insulin resistance. The adipokine adiponectin has 
reduced expression in obesity and appears to be protective against the development of type 2 
diabetes. Current recommendations to prevent type 2 diabetes center on lifestyle modiﬁ  cations, 
such as diet and exercise. Clinical trials have established the efﬁ  cacy of lifestyle intervention, as 
well as pharmacologic interventions that target glycemic control or fat metabolism. However, 
diabetes did develop in a substantial percentage of individuals who received intensive interven-
tion in these trials. Thus there is an unmet need for additional strategies in high-risk individuals. 
Recent data suggest thiazolidinediones and blockade of the endocannabinoid system represent 
novel therapeutic approaches that may be used for the prevention of diabetes. 
Keywords: cardiometabolic risk, abdominal obesity, dyslipidemia, diabetes, insulin resistance, 
endocannabinoid system
Burden of diabetes  
Type 2 diabetes is the most common metabolic disorder worldwide (Goldstein 2003), 
and its prevalence is growing at an alarming rate in both developed and developing 
countries (Wild et al 2004; Yach et al 2006). This growth has been related to the 
increased prevalence of obesity (deﬁ  ned as body mass index [BMI] 30 kg/m2), a 
primary driver in the development of type 2 diabetes, as well as an independent health 
problem (Centers for Disease Control and Prevention 2005; Diabetes Research Work-
ing Group 1999; Yach et al 2006). Moreover, an estimated 41 million people in the 
US currently have prediabetes, deﬁ  ned as impaired fasting glucose (IFG) or impaired 
glucose tolerance (IGT). These individuals have a high risk for the development of 
diabetes (Centers for Disease Control and Prevention 2006).
Type 2 diabetes is associated with considerable morbidity and mortality, which 
can lead to substantial personal and societal costs (Yach et al 2006). In 2002, in the 
US alone, direct and indirect costs attributable to diabetes were estimated at US$132 
billion by the American Diabetes Association (ADA) (Hogan et al 2003). This estimate 
does not include many intangible costs, such as pain and suffering. Cardiovascular 
disease (CVD) is the leading cause of death among diabetics, and is responsible 
for much of the increase in diabetes-related morbidity and mortality. CVD-related 
mortality is 2–4 times higher among diabetics (Centers for Disease Control and 
Prevention 2005). Atherosclerosis, hypertension, and stroke are common problems 
affecting individuals with diabetes, all of which correlate highly with the presence of 
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obesity (Centers for Disease Control and Prevention 2005; 
Glendening et al 2005).
A cluster of interrelated cardiometabolic risk factors 
is closely related to the development of type 2 diabetes 
and cardiovascular disease. Current views suggest that 
cardiometabolic risk factors represent a continuum of dis-
ease risks – not merely the presence or absence of a distinct 
disease entity (Eckel et al 2006). Obesity, hyperglycemia 
and insulin resistance, dyslipidemia, inﬂ  ammation, and 
hypertension represent interrelated therapeutic targets in the 
battle against the increasing prevalence of type 2 diabetes 
(Eckel et al 2006).
Obesity, insulin resistance, 
and progression to diabetes
The classiﬁ  cation and pathogenesis of type 2 diabetes involves 
abnormalities of glucose and lipid metabolism, including inad-
equate insulin secretion from pancreatic β cells and resistance 
to the action of insulin (ADA 2006; Goldstein 2003). There 
is epidemiologic and physiologic evidence linking insulin 
resistance and hyperglycemia (which precedes and charac-
terizes the development of type 2 diabetes) to the presence 
of abdominal obesity (Diabetes Research Working Group 
1999; Sharma 2006). An association between intra-abdominal 
adipose tissue and insulin resistance has been demonstrated 
in animal models and in human subjects (Raz et al 2005), and 
increased abdominal adipose tissue greatly increases the risk 
of developing IGT and insulin resistance in individuals with 
normal glucose tolerance at baseline (Hayashi et al 2003).
The underlying mechanisms involve the increased ﬂ  ux 
of free fatty acids (FFAs) to the liver, pancreas, and other 
tissues, and subsequent deposition of triglycerides (TG) 
(Lewis et al 2002; Raz et al 2005). This process is related 
to excessive release by adipose tissue of assorted bioactive 
substances known as adipokines (Chandran et al 2003), the 
combined actions of which trigger a chronic inﬂ  ammatory 
state that contributes to the development of insulin resistance 
(Xu et al 2003). Elevated circulating FFA levels cause tissues 
to become resistant to the action of insulin. Hyperinsulinemia 
results as a compensatory mechanism to maintain glucose 
tolerance under these conditions, a situation that can lead to 
pancreatic β cell damage and the development or worsening 
of glucose tolerance and diabetes (Lewis et al 2002; Zraika 
et al 2002; Goldstein 2003; Haber et al 2003; Raz et al 2005). 
In addition to adverse pancreatic effects, the excess glucose 
and fat in the blood can lead to additional organ and vascular 
damage, which underlies much of the morbidity and mortality 
associated with diabetes (Deedwania and Fonseca 2005; 
Centers for Disease Control and Prevention 2006).
The mechanisms by which abdominal obesity contribute 
to cardiometabolic risk appear to involve the endocrine activ-
ity of adipose tissue (Kershaw and Flier 2004). Adipose tissue 
and speciﬁ  cally abdominal adipose cells secrete a number of 
cytokines and adipokines that can have deleterious cardio-
metabolic effects. These include effects on glucose control, 
lipid proﬁ  le, increased thrombotic risk, and increased inﬂ  am-
matory state (Lewis et al 2002; Goldstein 2003). Secreted 
substances include (but are not limited to) C-reactive protein 
(CRP), a marker of inﬂ  ammation and cardiovascular risk 
(Berg and Scherer 2005; Natali et al 2006), and the inﬂ  am-
matory cytokines interleukin-6 (IL-6) and tumor necrosis 
factor-alpha (TNF-α) (Matsuzawa 2006; Natali et al 2006; 
Sharma 2006). These cytokines in turn induce expression of 
the adipocyte-derived secretory protein resistin, which has 
been implicated in induction of the inﬂ  ammatory cascade that 
contributes to the development of insulin resistance (Lehrke 
et al 2004). Additional adipokines that play a role in cardio-
metabolic risk include the thrombotic and ﬁ  brinolytic factors 
plasminogen-activator inhibitor type 1 (PAI-1) and ﬁ  brinogen 
(Matsuzawa 2006; Natali et al 2006; Sharma 2006), and 
components of the renin-angiotensin system (RAS) that 
are involved in the pathogenesis of hypertension, endothe-
lial dysfunction, and the development of insulin resistance 
(Reaven et al 1996; Caglayan et al 2005; Sharma 2006). 
Adiponectin, a serum protein synthesized exclusively 
by adipocytes, plays a role in cardiometabolic pathology 
(Scherer et al 1995; Hu et al 1996). This adipokine is a 
modulator of insulin sensitization, lipid metabolism, and 
inﬂ  ammatory states (Chandran et al 2003; Kadowaki et al 
2006; Matsuzawa 2006). In contrast to many of the inﬂ  am-
matory adipokines related to atherogenesis, and induction of 
insulin resistance, adiponectin has reduced expression under 
conditions of abdominal obesity, type 2 diabetes, and insulin 
resistance (Weyer et al 2001; Chandran et al 2003; Schulze 
et al 2004; Schulze et al 2005). Increased adiponectin levels 
are associated with lower hyperglycemia, dyslipidemia, and 
inﬂ  ammation in diabetic individuals, and appear protective 
against the development of type 2 diabetes in individuals at 
risk (Lindsay et al 2002; Krakoff et al 2003; Spranger et al 
2003). Low adiponectin levels are independently predictive 
of eventual type 2 diabetes even in apparently healthy (non-
obese) individuals (Lindsay et al 2002; Spranger et al 2003) 
and in patients with coronary artery disease and IFG (Knobler 
et al 2006). Genetic variability is attributable to plasma adi-
ponectin levels and may be an independent cardiovascular Vascular Health and Risk Management 2007:3(4) 513
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risk factor in diabetic individuals (Qi et al 2006). Although 
the mechanisms underlying the protective role of adiponectin 
are under investigation, several models have been proposed. 
These include adiponectin-mediated modiﬁ  cation of the 
insulin receptor in skeletal muscle, leading to enhanced 
signaling; increased FFA oxidation in skeletal muscle and 
liver, leading to a decrease in FFA ﬂ  ux; and decreased vas-
cular inﬂ  ammation through adiponectin-mediated effects on 
monocyte adhesion and on vascular proliferation of smooth 
muscle cells (Chandran et al 2003). Abdominal obesity and 
resultant adipokine dysregulation may be potential therapeu-
tic targets through lifestyle and/or pharmacologic approaches 
aimed at delaying or preventing the onset of type 2 diabetes 
in high-risk individuals.
Preventing the progression 
or onset of diabetes
Prediabetes (or IGT) is a major risk factor for diabetes, as 
are obesity, physical inactivity, and insulin resistance. It is 
well established that the risk for development or progression 
of type 2 diabetes can be modiﬁ  ed through lifestyle changes 
and/or pharmacotherapy. A number of well-designed clinical 
trials evaluating different strategies to prevent or delay 
type 2 diabetes have shown that lifestyle modiﬁ  cations and/or 
therapy with glucose-lowering agents used to treat this form 
of diabetes can signiﬁ  cantly prevent or delay its onset in 
individuals with IGT, irrespective of obesity (Sherwin et al 
2003; Klein et al 2004). The results of major, randomized, 
controlled clinical studies on the prevention of type 2 diabetes 
are summarized in Figure 1.
Intensive lifestyle modiﬁ  cation
The Da Qing IGT and Diabetes Study (Pan et al 1997) was 
an early long-term trial evaluating the impact of diet and/or 
exercise on the development of type 2 diabetes in more than 
110,660 individuals with IGT. After 6 years, the cumula-
tive incidence of diabetes was 68% in the control group, 
compared with 44% in the diet group, 41% in the exercise 
group, and 46% in the diet-plus-exercise group. The beneﬁ  t 
of lifestyle modiﬁ  cation was similar for the lean and over-
weight subgroups.
The Finnish study (Tuomilehto et al 2001) compared 
the impact of lifestyle modiﬁ  cation involving intensive 
individualized diet counseling and increased physical activity 
(intervention group) with that of brief diet and exercise coun-
seling (control group) in 522 obese males with IGT. After 
an average follow-up of 3.2 years, there was a 58% relative 
reduction in the incidence of diabetes in the intervention 
group compared with the control group. There was a clear 
correlation between diabetes risk reduction and the extent to 
which weight and activity goals were achieved. The impact 
of lifestyle intervention on insulin sensitivity and secretion, 
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Figure 1  Summary of the relative risk reduction (%) of new-onset type 2 diabetes in randomized, controlled clinical trials of prevention. Studies shown are the Da Qing 
IGT and Diabetes Study, which evaluated diet and exercise (Pan et al 1997); the Finnish Diabetes Prevention Study, which evaluated diet and exercise (Tuomilehto et al 
2001); the Diabetes Prevention Program (DPP) studies, which evaluated diet and exercise or metformin (Knowler et al 2002); the Study To Prevent Non-Insulin-Dependent 
Diabetes Mellitus (STOP-NIDDM), which evaluated acarbose; Troglitazone in Prevention of Diabetes (TRIPOD), which evaluated Troglitazone; XENical in the Prevention of 
Diabetes in Obese Subjects (XENDOS), which evaluated the gastrointestinal lipase inhibitor orlistat (Torgerson et al 2004); and a meta-analysis of 10 trials of RAS blockade 
with either ACE inhibitors or ARBs (Scheen 2004a). (See text for study details.)Vascular Health and Risk Management 2007:3(4) 514
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as measured using frequently sampled intravenous glucose 
tolerance testing, was evaluated after 4 years in a subset 
of these patients (Uusitupa et al 2003). There was a strong 
correlation between 4-year changes in insulin sensitivity and 
changes in weight. Insulin sensitivity improved by 64% among 
patients in the highest tertile of weight loss (a loss of –8% to 
–17%) and deteriorated by 24% among patients who gained 
weight (weight change of –1.4% to +10%). The acute insulin 
response declined signiﬁ  cantly among patients in the control 
group (ie, no intensive lifestyle modiﬁ  cation). Importantly, 
insulin secretion remained stable (ie, did not worsen) among 
patients with IGT at baseline who were able to lose weight.
Intensive lifestyle modiﬁ  cation and/
or pharmacologic intervention with 
glucose-lowering agents
The Diabetes Prevention Program (DPP) is one of the larg-
est and most extensive ongoing clinical trials evaluating this 
issue (Knowler et al 2002). Intensive nutrition and exercise 
counseling, metformin therapy, and placebo were compared 
among 3234 obese individuals with IGT in a randomized, 
controlled format. The latter 2 interventions were combined 
with standard diet and exercise recommendations. Following 
the 2.8-year follow-up, there was a 58% relative reduction 
in the progression to diabetes with lifestyle modiﬁ  cation 
(compared with controls), and a 31% relative reduction in 
progression in the metformin group. 
Pharmacologic intervention with 
glucose-lowering agents
Thiazolinedione (troglitazone) also has been evaluated 
as a preventive agent. The TRIPOD study monitored 
236 Hispanic women with a history of previous gesta-
tional diabetes who were randomized to receive either 
troglitazone or placebo (Buchanan et al 2002). After the 
median follow-up of 30 months, a 56% relative reduc-
tion in progression to diabetes in the troglitazone group 
was noted. Protection from diabetes was associated 
with a preservation of pancreatic β cell compensation 
for insulin resistance, as measured by acute insulin 
response to intravenous glucose administration and 
whole-body insulin sensitivity. The DPP group conducted 
a long-term comparison of treatment with metformin, 
troglitazone, placebo, or intensive lifestyle intervention 
in 2343 patients with IGT (Knowler et al 2005). During 
the study, concerns arose over the potential liver toxicity 
of troglitazone, leading to discontinuation of this study 
arm and the withdrawal of troglitazone from clinical use. 
Prior to troglitazone discontinuation (mean time of 0.9 
years), the incidence of diabetes was lower (3.0 cases 
per 100 person-years) than that observed for individuals 
receiving placebo, metformin, or intensive lifestyle in-
tervention (12.0, 6.7, and 5.1 cases per 100 person-years, 
respectively). This lower incidence was statistically sig-
nificant for the troglitazone-treated group versus both the 
placebo and metformin groups, but was not significant 
in comparison with lifestyle intervention (p < 0.001, 
p = 0.02, and p = 0.18, respectively). This protective 
effect observed in the troglitazone group persisted for 8 
months after discontinuation of the study drug. 
The Study To Prevent Non-Insulin-Dependent Diabetes 
Mellitus (STOP-NIDDM) was a randomized, placebo-
controlled trial designed to evaluate the α-glucosidase in-
hibitor acarbose in the prevention or delay of type 2 diabetes 
in 1368 individuals with IGT (Chiasson et al 2002). All 
patients were instructed to follow a weight-reducing or 
maintaining diet and were encouraged to exercise regularly. 
After the mean follow-up period of 3.3 years, diabetes had 
developed in 32% of patients treated with acarbose and in 
42% of placebo subjects, yielding a relative hazard rate of 
0.75 with acarbose treatment (p = 0.0015). Acarbose also 
signiﬁ  cantly increased reversion of IGT to normal glucose 
tolerance (p < 0.0001). This treatment generally was well 
tolerated; the most common adverse events that occurred 
during acarbose treatment were gastrointestinal effects such 
as ﬂ  atulence and diarrhea.
The DREAM (Diabetes REduction Assessment with 
ramipril and rosiglitazone Medication) trial prospectively 
assessed whether treatment with the thiazolidinedione 
rosiglitazone could reduce the frequency of diabetes in 
5269 individuals with IGT, IFG, or both (Gerstein et al 
2006). All participants were given information on diet 
and lifestyle modifications to delay or prevent diabetes. 
After the median follow-up of 3 years, diabetes or death 
was the outcome for 11.6% of rosiglitazone recipients and 
26.0% of placebo subjects (p < 0.0001). The incidence of 
regression to normoglycemia (defined as 2-hour and fast-
ing plasma glucose concentrations of <7.8 mmol/L and 
<6.1 mmol/L, respectively) was significantly greater in 
the rosiglitazone group (p < 0.0001 vs placebo).
Pharmacologic intervention with lipase 
inhibitor
The XENical in the Prevention of Diabetes in Obese Sub-
jects (XENDOS) trial was a 4-year, randomized, double-Vascular Health and Risk Management 2007:3(4) 515
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blind, placebo-controlled study conducted in 3,305 obese 
individuals to evaluate the efﬁ  cacy of lifestyle changes in 
conjunction with either the gastrointestinal lipase inhibitor 
orlistat or placebo in preventing or delaying type 2 diabetes 
(Torgerson et al 2004). Only 21% of patients had IGT at 
the time of study entry. After 4 years of treatment, a 37% 
reduction in the risk of developing diabetes was noted for the 
orlistat group (cumulative incidence: 6% and 9% with orlistat 
and placebo, respectively; p = 0.0032). This risk reduction 
was accompanied by a signiﬁ  cantly greater mean weight loss 
in the orlistat group compared with placebo (5.8 vs 3.0 kg, 
respectively; p < 0.001). Further analysis suggested that the 
reduced risk of developing diabetes could be explained by 
an effect on the group with IGT at baseline.
Underlying mechanisms of prevention
A number of studies have identiﬁ  ed mechanistic bases for 
the beneﬁ  ts of lifestyle and/or pharmacologic intervention in 
the delay or prevention of diabetes. As expected, the beneﬁ  ts 
appear to be mediated by effects on multiple potentially 
causative emerging risk factors related to inﬂ  ammation, 
adipokine dysregulation, ﬁ  brinolysis, insulin resistance, and 
glucose metabolism. For example, lifestyle intervention in 
subjects participating in the Finnish Diabetes Prevention 
Study was associated with decreased expression of PAI-1 
and ﬁ  brinogen, both mediators of ﬁ  brinolysis (Hamalainen 
et al 2005).
The thiazolidinediones troglitazone, rosiglitazone, 
and pioglitazone (Ghanim et al 2006; Samaha et al 2006; 
Szapary et al 2006) have early anti-inflammatory ef-
fects, which are associated with decreased lipolysis and 
FFA flux, improved insulin signaling and sensitization, 
increased adiponectin expression, and improved lipid pro-
files (eg, elevated high-density lipoprotein [HDL] choles-
terol levels and favorable changes in lipoprotein particle 
size). These beneficial effects of thiazolidinediones on 
cardiometabolic risk factors have been observed in obese 
and non-obese patients with type 2 diabetes (Chiquette et 
al 2004; Ghanim et al 2006) and in nondiabetic patients 
with metabolic syndrome (Samaha et al 2006; Szapary 
et al 2006). This interrelationship of factors confirms the 
concept of metabolic risk being a continuum of disease 
processes and not merely the absence or presence of one 
or all of these cardiometabolic risk factors.
Renin-angiotensin blockade
Large randomized clinical trials have demonstrated that 
blockade of the RAS with angiotensin-converting enzyme 
(ACE) inhibition or angiotensin receptor blockers (ARBs) 
can reduce the incidence of new-onset type 2 diabetes. 
A recent meta-analysis of 10 randomized clinical trials 
involving more than 76,000 patients assessed the potential 
prevention of diabetes through RAS blockade (Scheen 
2004a), including 5 trials of ACE inhibitors (enalapril, 
lisinopril, captopril, and ramipril) and 4 of ARBs (losartan, 
candesartan, and valsartan). Among all these trials, new cases 
of type 2 diabetes were found in 7.4% of patients treated with 
an ACE inhibitor or ARB, compared with 9.6% of control 
patients. This corresponded to a 22% relative risk reduction 
of developing type 2 diabetes (p < 0.00001). Despite these 
positive ﬁ  ndings on the preventive effects of ACE inhibitors, 
it was recently reported that ramipril (included as a treatment 
arm in the DREAM study) failed to reduce the incidence of 
the primary outcome (diabetes or death) among participants 
with IFG or IGT over the median 3-year treatment period 
(Bosch et al 2006). However, individuals receiving ramipril 
in this study were more likely to have normal fasting glucose 
levels or glucose tolerance at study endpoint than those re-
ceiving placebo. This suggests that the study may not have 
had adequate power to discern a difference; a longer or larger 
study might be required for detecting an effect of the ACE 
inhibitor on the incidence of diabetes.
The mechanisms involved in the actions of ACE inhibi-
tors and ARBs in diabetes prevention are not fully under-
stood. The multiple physiologic actions of angiotensin II 
may in part explain this complexity (Deedwania and Fonseca 
2005). It is likely that the beneﬁ  cial actions of RAS blockade 
involve improvement in both insulin sensitivity and insulin 
secretion through the impact of multiple mediators on insulin 
action and receptor signaling, muscle pancreatic islet blood 
ﬂ  ow, sympathetic nervous activity, adipokine production, 
and lipid metabolism (Scheen 2004b). For example, it was 
recently shown that losartan improves insulin sensitivity by 
increasing adiponectin production and decreasing TNF-α 
production (Park et al 2006). There is also evidence that 
elevated angiotensin II produced by large insulin-resistant 
adipocytes may inhibit the recruitment of pre-adipocytes, 
resulting in increased lipid storage in muscle and decreased 
insulin sensitivity (Sharma et al 2002).
Impact of dietary choice
Both large randomized trials (The Finnish and DPP studies) 
and many smaller ones have demonstrated a signiﬁ  cant impact 
of intensive lifestyle modiﬁ  cation using conventional dietary 
recommendations for overweight or obese persons at risk for 
the development of diabetes; such diets are low in saturated Vascular Health and Risk Management 2007:3(4) 516
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fats and total fat intake, and rich in complex carbohydrates 
(Knowler et al 2002; Tuomilehto et al 2001; Klein et al 2004). 
However, there has been growing interest in low-carbohydrate 
diets as therapy for obesity. Overall, recent prospective trials 
indicate similar weight-loss efﬁ  cacy over the long term with 
low-fat and carbohydrate-restricted diets (Samaha 2005). The 
combined results of 5 recent randomized controlled trials indi-
cate that subjects receiving a low-carbohydrate, high-fat diet 
achieved greater short- but not long-term weight loss than those 
receiving a conventional diet (Klein et al 2004). However, 
some data suggest that high-fat diets, while having similar 
effects on weight, may have more favorable effects on lipid 
proﬁ  le and glycemic status in obese patients. In a 6-month 
study in 79 severely obese patients with a high prevalence 
of metabolic syndrome or diabetes, a carbohydrate-restricted 
diet was associated with relative improvement in insulin sen-
sitivity and TG levels compared with a low-fat diet (Samaha 
et al 2003). A carbohydrate-restricted diet also was associated 
with more favorable effects on lipoprotein subfractions and 
on inﬂ  ammation as measured by CRP levels in these patients 
(Seshadri et al 2004). In a 1-year follow-up of the latter study, 
weight loss was still similar for the 2 groups, and effects on 
atherogenic dyslipidemia and glycemia had remained more 
favorable in the group on a low-carbohydrate diet (Stern et al 
2004). Although these ﬁ  ndings are compelling, outcomes 
studies evaluating the impact of carbohydrate-restricted diet 
on diabetes development and other cardiovascular outcomes 
are needed before recommendations regarding such a diet 
are warranted.
Drugs with potential application 
to prevention
Pharmacologic intervention enhancing 
incretin action
The incretin hormone glucagon-like peptide-1 (GLP-1) 
has demonstrated a variety of antidiabetic effects, includ-
ing stimulation of insulin secretion, inhibition of glucagon 
secretion, delay of gastric emptying, suppression of ap-
petite, promotion of β cell proliferation, and inhibition of 
β cell apoptosis (Drucker 2006). Native GLP-1 has limited 
clinical use because it is rapidly inactivated by the enzyme 
dipeptidyl peptidase-4 (DPP-4), resulting in a half-life of 
<2 minutes. To overcome this obstacle, GLP-1 analogues 
have been developed with low afﬁ  nity for DPP-4 as well as 
inhibitors of DPP-4. The GLP-1 mimetic exenatide and the 
DPP-4 inhibitor sitagliptin are now available for clinical use. 
Preclinical evidence suggests that exenatide may delay onset 
or prevent development of diabetes (Wang and Brubaker 
2002; Stoffers et al 2003), although these ﬁ  ndings need 
conﬁ  rmation in clinical studies.
Exenatide has demonstrated efﬁ  cacy in randomized con-
trolled studies when used as adjunct therapy in patients with 
type 2 diabetes and inadequate glycemic control while receiv-
ing metformin (n = 336) (DeFronzo et al 2005), a sulfonyl-
urea (n = 377) (Buse et al 2004), or metformin/sulfonylurea 
(n = 733) (Kendall et al 2005). The recommended dosages 
are 5 or 10 µg subcutaneously, twice daily. In addition to 
improving glycemic control, treatment with exenatide for 
30 weeks reduced body weight by 0.9–1.6 kg with the lower 
dose and by 1.6–2.8 kg with the higher dose, compared with 
reductions of 0.3–0.9 kg in placebo recipients (Buse et al 
2004; DeFronzo et al 2005; Kendall et al 2005). In each study, 
dose-related nausea was the most common adverse event in 
exenatide-treated patients (low dose, 36%–39%; high dose, 
45%–51%). No correlation between change in body weight 
and nausea was observed in any of the studies.
Sitagliptin was recently approved as monotherapy, or in 
combination with metformin or a peroxisome proliferator-
activated receptor gamma agonist, to improve glycemic control 
in patients with type 2 diabetes. The recommended oral dosage 
of sitagliptin is 100 mg once daily, with dosage adjustments 
required for patients with moderate or severe end-stage renal 
disease. Pharmacokinetic studies support once-daily dosing 
and show a lack of interaction between sitagliptin and metfor-
min (Bergman et al 2006; Herman et al 2005, 2006). Based on 
prescribing information, treatment with sitagliptin improves 
glycemic control (JanuviaTM prescribing information 2006). 
No signiﬁ  cant effects on body weight were reported, although 
the duration of treatment (up to 24 weeks) was shorter than 
that for exenatide. The most common adverse events were 
nasopharyngitis (5%) in patients receiving sitagliptin alone, 
and upper respiratory tract infection (6%) and headache 
(5%) in patients receiving sitagliptin/pioglitazone (JanuviaTM 
prescribing information 2006).
Pharmacologic intervention inhibiting 
serotonin and norepinephrine reuptake 
Numerous clinical studies have been conducted with the 
serotonin and norepinephrine reuptake inhibitor sibutramine, 
which is thought to induce weight loss by increasing satiety 
and possibly energy expenditure (Poston and Foreyt 2004). 
Sibutramine is indicated for the management of obesity in 
conjunction with a reduced-calorie diet. It is administered 
orally at dosages of 5–15 mg once daily. The effects of 
sibutramine on body weight are well established, as described Vascular Health and Risk Management 2007:3(4) 517
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below. However, no study has assessed whether this agent 
can delay or prevent the development of type 2 diabetes.
In a large systematic review involving 29 random-
ized controlled trials of obese patients who were healthy 
(n = 3604) or who had type 2 diabetes (n = 654), hyperlipid-
emia (n = 341), hypertension (n = 340), or obstructive sleep 
apnea (n = 40), sibutramine 10–20 mg/day was associated 
with a placebo-subtracted mean weight loss of 2.8 kg in 8- 
to 12-week studies, 5.16 kg in 16- to 24-week studies, and 
4.5 kg in 44- to 54-week studies (Arterburn et al 2004). No 
dose-response was observed. Body-weight reductions were 
consistent across the different study populations. A recent 
meta-analysis of 8 randomized, double-blind, placebo-con-
trolled trials, which was restricted to obese patients with type 
2 diabetes (n = 1093), yielded similar beneﬁ  ts with regard to 
body-weight reductions (Vettor et al 2005). In both analyses, 
cardiovascular and metabolic ﬁ  ndings were more modest and 
included increases in heart rate and blood pressure, improve-
ments in triglyceride and HDL cholesterol levels and, among 
patients with type 2 diabetes, improvements in glycemic 
control (Arterburn et al 2004; Vettor et al 2005). The car-
diovascular effects of sibutramine necessitate monitoring of 
blood pressure and heart rate prior to initiating therapy and 
at regular intervals during therapy; sibutramine should not 
be used in patients with a history of coronary artery disease, 
congestive heart failure, arrhythmias, or stroke (Meridia® 
prescribing information 2006).
Blockade of the endocannabinoid (EC) 
system 
Blockade of the EC system represents a novel therapeutic 
modality that targets intra-abdominal obesity, glycemic 
regulation, and related cardiometabolic risk factors. Animal 
studies have shown that this system plays a role in energy 
intake and homeostasis as well as excessive food intake (De 
Petrocellis et al 2004; Di Marzo et al 2004). The EC system 
is overactivated in obesity (Di Marzo et al 2001), and there 
is growing evidence that its activity may impact a number of 
cardiometabolic parameters associated with obesity (Despres 
et al 2006; John et al 2006).
Promising preclinical ﬁ  ndings have led to the develop-
ment of selective CB1 antagonists for clinical use. Several 
are currently in development, with one (rimonabant) now in 
Phase III testing (Antel et al 2006). The efﬁ  cacy and safety 
of CB1 blockade have been investigated in patients with 
obesity, with or without co-morbidities, in a clinical develop-
ment program (Rimonabant in Obesity; RIO) (Lebovitz et al 
2006) involving 4 large trials; the results of 3 trials have been 
published in full (Despres et al 2005; Van Gaal et al 2005; 
Pi-Sunyer et al 2006; Scheen et al 2006).
Treatment with rimonabant 20 mg for 1 year induced a 
consistent reduction in waist circumference and weight in all 
4 trials (Despres et al 2005; Van Gaal et al 2005; Pi-Sunyer 
et al 2006; Scheen et al 2006). Improvements in HDL and 
TG levels also were observed and, as in the animal studies, 
much of this effect (approximately 50%) was not attribut-
able to the weight decrease. These beneﬁ  ts were maintained 
throughout the second year of follow-up. 
The potential beneﬁ  t of rimonabant therapy on gly-
cemic and other cardiometabolic parameters has been 
investigated in RIO-Diabetes (Scheen et al 2006), which 
involved 1045 patients with type 2 diabetes. In addition to 
the signiﬁ  cant reduction in weight and waist circumfer-
ence observed in all RIO studies, rimonabant 20 mg/day 
for 1 year produced a 0.7% reduction in hemoglobin A1c 
(HbA1C) versus placebo, with 43% of patients achieving 
HbA1C levels below 6.5%. Again, much of this effect was 
independent of weight change. Consistent with the other 
RIO trials, improvements from baseline in cardiometabolic 
parameters also were noted, including beneﬁ  cial effects on 
HDL cholesterol and TG.
To explore the association between abdominal obesity 
and the development of diabetes, pooled data from RIO-
Europe, RIO-North America, and RIO-Lipids were used 
to assess the effects of rimonabant on the development 
of diabetes in obese individuals who were classified 
with prediabetes at study enrolment (Rosenstock 2005). 
Prediabetes, or IFG, was defined as fasting glucose levels 
>5.6 mmol/L (100 mg/dL) and <7 mmol/L (126 mg/dL). 
This analysis involved 1290 patients participating in the 3 
studies. Significant reductions were observed for fasting 
insulin levels (–2.7 ΜIU/mL; p < 0.001 vs placebo) and 
for homeostasis model assessment of insulin resistance 
(HOMA-IR) (–0.8%; p = 0.002 vs placebo). A trend 
toward halting or delaying the progression of IFG was 
suggested by the greater percentage of patients whose 
fasting glucose level became normal (46% vs 39% for 
rimonabant 20 mg vs placebo, respectively). In addition, 
a smaller percentage of rimonabant recipients progressed 
to type 2 diabetes (3.6% vs 4.9% for rimonabant 20 mg 
vs placebo, respectively); however, statistical analyses 
of these comparisons were not provided. The potential 
of rimonabant to delay or prevent the onset of type 2 
diabetes is undergoing more extensive study in a clinical 
trial of patients with prediabetes (US National Institutes 
of Health 2006).Vascular Health and Risk Management 2007:3(4) 518
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Conclusion
Although lifestyle intervention has proven successful in clini-
cal trials, there are barriers to its long-term success for many 
individuals, such as cost, communication with healthcare pro-
viders, and the difﬁ  culty in maintaining substantial lifestyle 
changes long term (Vijan et al 2005). In the DPP studies, 49% 
and 74% of lifestyle participants met their weight loss and 
activity goals, respectively, at the end of 6 months; however, 
the success rates declined to 37% and 67%, respectively, over 
the 3.2-year follow-up period (Wing et al 2004). Despite the 
reduced risk that accompanies even modest weight loss (eg, 
5% of body weight) (Klein et al 2004), diabetes developed 
in a substantial number of patients with active intervention 
in the randomized clinical trials (Figure 1). There is a current 
medical need for additional preventive intervention strategies 
in overweight and obese patients, particularly those at high 
risk for the development of type 2 diabetes.
Current guidelines do not advocate speciﬁ  c preven-
tive pharmacologic therapy for prediabetes, although 
aggressive therapy for patients with cardiovascular risk 
factors (eg, hypertension) is recommended and has been 
beneﬁ  cial in preventing type 2 diabetes in these patients. 
More aggressive preventive therapy, the adoption of novel 
therapeutic approaches, and possibly modiﬁ  cation of cur-
rent treatment guidelines in patients at high risk should be 
considered as strategies to reduce the growing burden of 
type 2 diabetes.
Acknowledgments
Funding for editorial support was provided by Sanoﬁ  -
Aventis US.
References
American Diabetes Association. 2006. Standards of medical care in 
diabetes- – 2006. Diabetes Care, 29(Suppl 1):S4–42.
Antel J, Gregory PC, Nordheim U. 2006. CB1 cannabinoid receptor antago-
nists for treatment of obesity and prevention of comorbid metabolic 
disorders. J Med Chem, 49:4008–16.
Arterburn DE, Crane PK, Veenstra DL. 2004. The efﬁ  cacy and safety of 
sibutramine for weight loss: a systematic review. Arch Intern Med, 
164:994–1003.
Berg AH, Scherer PE. 2005. Adipose tissue, inﬂ  ammation, and cardiovas-
cular disease. Circ Res, 96:939–49.
Bergman AJ, Stevens C, Zhou Y, et al. 2006. Pharmacokinetic and 
pharmacodynamic properties of multiple oral doses of sitagliptin, 
a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, 
placebo-controlled study in healthy male volunteers. Clin Ther, 
28:55–72.
Bosch J, Yusuf S, Gerstein HC, et al. 2006. Effect of ramipril on the incidence 
of diabetes. N Engl J Med, 355:1551–62.
Buchanan TA, Xiang AH, Peters RK, et al. 2002. Preservation of pancreatic 
beta-cell function and prevention of type 2 diabetes by pharmacological 
treatment of insulin resistance in high-risk hispanic women. Diabetes, 
51:2796–803.
Buse JB, Henry RR, Han J, et al. 2004. Effects of exenatide (exendin-4) on 
glycemic control over 30 weeks in sulfonylurea-treated patients with 
type 2 diabetes. Diabetes Care, 27:2628–35.
Caglayan E, Blaschke F, Takata Y, et al. 2005. Metabolic syndrome-inter-
dependence of the cardiovascular and metabolic pathways. Curr Opin 
Pharmacol, 5:135–42.
Centers for Disease Control and Prevention. 2005. National diabetes fact 
sheet: general information and national estimates on diabetes in the 
United States, 2005. Atlanta, GA: U.S. Department of Health and Hu-
man Services, Centers for Disease Control and Prevention. 
Centers for Disease Control and Prevention. 2006. Diabetes: Disabling, 
deadly, and on the rise. U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, Coordinating Center for 
Health Promotion. 
Chandran M, Phillips SA, Ciaraldi T, et al. 2003. Adiponectin: more than 
just another fat cell hormone? Diabetes Care, 26:2442–50.
Chiasson JL, Josse RG, Gomis R, et al. 2002. Acarbose for prevention of 
type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 
359:2072–7.
Chiquette E, Ramirez G, Defronzo R. 2004. A meta-analysis comparing the 
effect of thiazolidinediones on cardiovascular risk factors. Arch Intern 
Med, 164:2097–104.
De Petrocellis L, Cascio MG, Di M, V. 2004. The endocannabinoid 
system: a general view and latest additions. Br J Pharmacol, 
141:765–74.
Deedwania PC, Fonseca VA. 2005. Diabetes, prediabetes, and cardiovascular 
risk: shifting the paradigm. Am J Med, 118:939–47.
DeFronzo RA, Ratner RE, Han J, et al. 2005. Effects of exenatide (exendin-
4) on glycemic control and weight over 30 weeks in metformin-treated 
patients with type 2 diabetes. Diabetes Care, 28:1092–100.
Despres JP, Golay A, Sjostrom L. 2005. Effects of rimonabant on metabolic 
risk factors in overweight patients with dyslipidemia. N Engl J Med, 
353:2121–34.
Despres JP, Lemieux I, Almeras N. 2006. Contribution of CB1 blockade 
to the management of high-risk abdominal obesity. Int J Obes (Lond), 
30(Suppl 1):S44–S52.
Di Marzo V, Bifulco M, De Petrocellis L. 2004. The endocannabinoid 
system and its therapeutic exploitation. Nat Rev Drug Discov, 
3:771–84.
Di Marzo V, Goparaju SK, Wang L, et al. 2001. Leptin-regulated 
endocannabinoids are involved in maintaining food intake. Nature, 
410:822–5.
Diabetes Research Working Group. 1999. Conquering diabetes. A strategic 
plan for the 21st century. NIH Publication No. 99–4398. National 
Institutes of Health. 
Drucker DJ. 2006. The biology of incretin hormones. Cell Metab, 
3:153–65.
Eckel RH, Kahn R, Robertson RM, et al. 2006. Preventing cardio-
vascular disease and diabetes: a call to action from the American 
Diabetes Association and the American Heart Association. Circula-
tion, 113:2943–6.
Gerstein HC, Yusuf S, Bosch J, et al. 2006. Effect of rosiglitazone on the 
frequency of diabetes in patients with impaired glucose tolerance 
or impaired fasting glucose: a randomised controlled trial. Lancet, 
368:1096–105.
Ghanim H, Dhindsa S, Aljada A, et al. 2006. Low-dose rosiglitazone exerts 
an antiinﬂ  ammatory effect with an increase in adiponectin indepen-
dently of free fatty acid fall and insulin sensitization in obese type 2 
diabetics. J Clin Endocrinol Metab, 91:3553–8.
Glendening PN, Hearne SA, Segal LM, et al. 2005. F as in fat: How obesity 
policies are failing in America. Trust for America’s Health. Available at: 
http://healthyamericans.org/reports/obesity2005/Obesity2005Report.
pdf.
Goldstein BJ. 2003. Insulin resistance: from benign to type 2 diabetes mel-
litus. Rev Cardiovasc Med, 4(Suppl 6):S3-10.
Haber EP, Ximenes HM, Procopio J, et al. 2003. Pleiotropic effects of fatty 
acids on pancreatic beta-cells. J Cell Physiol, 194:1–12.Vascular Health and Risk Management 2007:3(4) 519
Type 2 diabetes burden
Hamalainen H, Ronnemaa T, Virtanen A, et al. 2005. Improved ﬁ  brinolysis by an 
intensive lifestyle intervention in subjects with impaired glucose tolerance. 
The Finnish Diabetes Prevention Study. Diabetologia, 48:2248–53.
Hayashi T, Boyko EJ, Leonetti DL, et al. 2003. Visceral adiposity and the 
risk of impaired glucose tolerance: a prospective study among Japanese 
Americans. Diabetes Care, 26:650–5.
Herman GA, Bergman A, Yi B, et al. 2006. Tolerability and pharmacokinet-
ics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin 
when co-administered in patients with type 2 diabetes. Curr Med Res 
Opin, 22:1939–47.
Herman GA, Stevens C, Van Dyck K, et al. 2005. Pharmacokinetics and 
pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase 
IV, in healthy subjects: results from two randomized, double-blind, 
placebo-controlled studies with single oral doses. Clin Pharmacol 
Ther, 78:675–88.
Hogan P, Dall T, Nikolov P. 2003. Economic costs of diabetes in the US in 
2002. Diabetes Care, 26:917–32.
Hu E, Liang P, Spiegelman BM. 1996. AdipoQ is a novel adipose-speciﬁ  c 
gene dysregulated in obesity. J Biol Chem, 271:10697–703.
JanuviaTM. 2006. JanuviaTM (sitagliptin) prescribing information. Merck & 
Co. Inc [online]. URL: http://www.merck.com/product/usa/pi_circulars/
j/januvia/januvia_pi.pdf.
John BJ, Irukulla S, Abulaﬁ   AM, et al. 2006. Systematic review: adipose 
tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther, 
23:1511–23.
Kadowaki T, Yamauchi T, Kubota N, et al. 2006. Adiponectin and adiponec-
tin receptors in insulin resistance, diabetes, and the metabolic syndrome. 
J Clin Invest, 116:1784–92.
Kendall DM, Riddle MC, Rosenstock J, et al. 2005. Effects of exenatide 
(exendin-4) on glycemic control over 30 weeks in patients with 
type 2 diabetes treated with metformin and a sulfonylurea. Diabetes 
Care,,28:1083–91.
Kershaw EE, Flier JS. 2004. Adipose tissue as an endocrine organ. J Clin 
Endocrinol Metab, 89:2548–56.
Klein S, Sheard NF, Pi-Sunyer X, et al. 2004. Weight management through life-
style modiﬁ  cation for the prevention and management of type 2 diabetes: 
rationale and strategies: a statement of the American Diabetes Associa-
tion, the North American Association for the Study of Obesity, and the 
American Society for Clinical Nutrition. Diabetes Care, 27:2067–73.
Knobler H, Benderly M, Boyko V, et al. 2006. Adiponectin and the develop-
ment of diabetes in patients with coronary artery disease and impaired 
fasting glucose. Eur J Endocrinol, 154:87–92.
Knowler WC, Barrett-Connor E, Fowler SE, et al. 2002. Reduction in the 
incidence of type 2 diabetes with lifestyle intervention or metformin. 
N Engl J Med, 346:393–403.
Knowler WC, Hamman RF, Edelstein SL, et al. 2005. Prevention of 
type 2 diabetes with troglitazone in the Diabetes Prevention Program. 
Diabetes, 54:1150–6.
Krakoff J, Funahashi T, Stehouwer CD, et al. 2003. Inﬂ  ammatory markers, 
adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes 
Care, 26:1745–51.
Lebovitz HE, Austin MM, Blonde L, et al. 2006. ACE/AACE consensus 
conference on the implementation of outpatient management of diabe-
tes mellitus: consensus conference recommendations. Endocr Pract, 
12(Suppl 1):6–12.
Lehrke M, Reilly MP, Millington SC, et al. 2004. An inflamma-
tory cascade leading to hyperresistinemia in humans. PLoS Med, 
1:161–8.
Lewis GF, Carpentier A, Adeli K, et al. 2002. Disordered fat storage and 
mobilization in the pathogenesis of insulin resistance and type 2 
diabetes. Endocr Rev, 23:201–29.
Lindsay RS, Funahashi T, Hanson RL, et al. 2002. Adiponectin and 
development of type 2 diabetes in the Pima Indian population. Lancet, 
360:57–8.
Matsuzawa Y. 2006. Therapy Insight: adipocytokines in metabolic syn-
drome and related cardiovascular disease. Nat Clin Pract Cardiovasc 
Med, 3:35–42.
Meridia®. 2006. Meridia® (sibutramine hydrochloride monohydrate) 
prescribing information. Abbott Laboratories [online]. URL: http://
rxabbott.com/pdf/meridia.pdf.
Natali A, Toschi E, Baldeweg S, et al. 2006. Clustering of insulin resistance 
with vascular dysfunction and low-grade inﬂ  ammation in type 2 dia-
betes. Diabetes, 55:1133–40.
Pan XR, Li GW, Hu YH, et al. 1997. Effects of diet and exercise in prevent-
ing NIDDM in people with impaired glucose tolerance. The Da Qing 
IGT and Diabetes Study. Diabetes Care, 20:537–44.
Park H, Hasegawa G, Obayashi H, et al. 2006. Relationship between insulin 
resistance and inﬂ  ammatory markers and anti-inﬂ  ammatory effect of 
losartan in patients with type 2 diabetes and hypertension. Clin Chim 
Acta, 374:129–34.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. 2006. Effect of rimonabant, 
a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk 
factors in overweight or obese patients: RIO-North America: a random-
ized controlled trial. JAMA, 295:761–75.
Poston WS, Foreyt JP. 2004. Sibutramine and the management of obesity. 
Expert Opin Pharmacother, 5:633–42.
Qi L, Doria A, Manson JE, et al. 2006. Adiponectin genetic variability, 
plasma adiponectin, and cardiovascular risk in patients with type 2 
diabetes. Diabetes, 55:1512–6.
Raz I, Eldor R, Cernea S, et al. 2005. Diabetes: insulin resistance and 
derangements in lipid metabolism. Cure through intervention in fat 
transport and storage. Diabetes Metab Res Rev, 21:3–14.
Reaven GM, Lithell H, Landsberg L. 1996. Hypertension and associated 
metabolic abnormalities--the role of insulin resistance and the sympa-
thoadrenal system. N Engl J Med, 334:374–81.
Rosenstock J. 2005. The potential of rimonabant in prediabetes: Pooled 
1-year results from the RIO-Lipids, RIO-Europe and RIO-North 
American studies [abstract]. Presented at the 65th Annual Meeting of 
the American Diabetes Association, Abstract 13-LB.
Samaha FF. 2005. Effect of very high-fat diets on body weight, lipoproteins, 
and glycemic status in the obese. Curr Atheroscler Rep, 7:412–20.
Samaha FF, Iqbal N, Seshadri P, et al. 2003. A low-carbohydrate as 
compared with a low-fat diet in severe obesity. N Engl J Med, 
348:2074–81.
Samaha FF, Szapary PO, Iqbal N, et al. 2006. Effects of rosiglitazone on 
lipids, adipokines, and inﬂ  ammatory markers in nondiabetic patients 
with low high-density lipoprotein cholesterol and metabolic syndrome. 
Arterioscler Thromb Vasc Biol, 26:624–30.
Scheen A, Finer N, Hollander P, et al. 2006. Rimonabant improves 
cardiometabolic risk factors in overweight/obese patients with type 
2 diabetes irrespective of background oral antidiabetic therapy (met-
formin or sulfonylureas) [abstract]. Diabetes, 55(Suppl 1):A133-4. 
Abstract 560-P.
Scheen AJ. 2004a. Renin-angiotensin system inhibition prevents type 2 
diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. 
Diabetes Metab, 30:487–96.
Scheen AJ. 2004b. Renin-angiotensin system inhibition prevents type 2 
diabetes mellitus. Part 2. Overview of physiological and biochemical 
mechanisms. Diabetes Metab, 30:498–505.
Scherer PE, Williams S, Fogliano M, et al. 1995. A novel serum protein 
similar to C1q, produced exclusively in adipocytes. J Biol Chem, 
270:26746–9.
Schulze MB, Rimm EB, Shai I, et al. 2004. Relationship between adiponectin 
and glycemic control, blood lipids, and inﬂ  ammatory markers in men 
with type 2 diabetes. Diabetes Care, 27:1680–7.
Schulze MB, Shai I, Rimm EB, et al. 2005. Adiponectin and future coro-
nary heart disease events among men with type 2 diabetes. Diabetes, 
54:534–9.
Seshadri P, Iqbal N, Stern L, et al. 2004. A randomized study comparing the 
effects of a low-carbohydrate diet and a conventional diet on lipoprotein 
subfractions and C-reactive protein levels in patients with severe obesity. 
Am J Med, 117:398–405.
Sharma AM. 2006. The obese patient with diabetes mellitus: from research 
targets to treatment options. Am J Med, 119:S17–23.Vascular Health and Risk Management 2007:3(4) 520
Iqbal
Sharma AM, Janke J, Gorzelniak K, et al. 2002. Angiotensin blockade 
prevents type 2 diabetes by formation of fat cells. Hypertension, 
40:609–11.
Sherwin RS, Anderson RM, Buse JB, et al. 2003. The prevention or delay 
of type 2 diabetes. Diabetes Care, 26(Suppl 1):S62–9.
Spranger J, Kroke A, Mohlig M, et al. 2003. Adiponectin and protection 
against type 2 diabetes mellitus. Lancet, 361:226–8.
Stern L, Iqbal N, Seshadri P, et al. 2004. The effects of low-carbohydrate 
versus conventional weight loss diets in severely obese adults: one-year 
follow-up of a randomized trial. Ann Intern Med, 140:778–85.
Stoffers DA, Desai BM, DeLeon DD, et al. 2003. Neonatal exendin-4 pre-
vents the development of diabetes in the intrauterine growth retarded 
rat. Diabetes, 52:734–40.
Szapary PO, Bloedon LT, Samaha FF, et al. 2006. Effects of pioglitazone 
on lipoproteins, inﬂ  ammatory markers, and adipokines in nondiabetic 
patients with metabolic syndrome. Arterioscler Thromb Vasc Biol, 
26:182–8.
Torgerson JS, Hauptman J, Boldrin MN, et al. 2004. XENical in the preven-
tion of diabetes in obese subjects (XENDOS) study: a randomized study 
of orlistat as an adjunct to lifestyle changes for the prevention of type 
2 diabetes in obese patients. Diabetes Care, 27:155–61.
Tuomilehto J, Lindstrom J, Eriksson JG, et al. 2001. Prevention of type 2 
diabetes mellitus by changes in lifestyle among subjects with impaired 
glucose tolerance. N Engl J Med, 344:1343–50.
US National Institutes of Health. ClinicalTrials.gov. 2006. [online] Accessed 
17 October 2006. URL: http://www.clinicaltrials.gov/ct/show/NCT0032
5650;jsessionid=DE34C9537828718F3BB395432F702959?order=4.
Uusitupa M, Lindi V, Louheranta A, et al. 2003. Long-term improvement 
in insulin sensitivity by changing lifestyles of people with impaired 
glucose tolerance: 4-year results from the Finnish Diabetes Prevention 
Study. Diabetes, 52:2532–8.
Van Gaal LF, Rissanen AM, Scheen AJ, et al. 2005. Effects of the 
cannabinoid-1 receptor blocker rimonabant on weight reduction and 
cardiovascular risk factors in overweight patients: 1-year experience 
from the RIO-Europe study. Lancet, 365:1389–97.
Vettor R, Serra R, Fabris R, et al. 2005. Effect of sibutramine on weight 
management and metabolic control in type 2 diabetes: a meta-analysis 
of clinical studies. Diabetes Care, 28:942–9.
Vijan S, Stuart NS, Fitzgerald JT, et al. 2005. Barriers to following dietary 
recommendations in Type 2 diabetes. Diabet Med, 22:32–8.
Wang Q, Brubaker PL. 2002. Glucagon-like peptide-1 treatment delays 
the onset of diabetes in 8 week-old db/db mice. Diabetologia, 
45:1263–73.
Weyer C, Funahashi T, Tanaka S, et al. 2001. Hypoadiponectinemia in 
obesity and type 2 diabetes: close association with insulin resistance 
and hyperinsulinemia. J Clin Endocrinol Metab, 86:1930–5.
Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care, 
27:1047–53.
Wing RR, Hamman RF, Bray GA, et al. 2004. Achieving weight and activity 
goals among diabetes prevention program lifestyle participants. Obes 
Res, 12:1426–34.
Xu H, Barnes GT, Yang Q, et al. 2003. Chronic inﬂ  ammation in fat plays a 
crucial role in the development of obesity-related insulin resistance. J 
Clin Invest, 112:1821–30.
Yach D, Stuckler D, Brownell KD. 2006. Epidemiologic and economic 
consequences of the global epidemics of obesity and diabetes. Nat 
Med, 12:62–6.
Zraika S, Dunlop M, Proietto J, et al. 2002. Effects of free fatty acids on 
insulin secretion in obesity. Obes Rev, 3:103–12.